A股異動丨仙樂健康漲超6% 擬8.71億元收購美國CDMO企業
格隆匯12月9日丨仙樂健康(300791.SZ)再度拉昇漲超6%,近5個交易日累計漲幅達20%,現報37.7元,總市值68億元。公司昨晚發佈關於收購Best Formulations股權方案調整的公吿。方案調整後,仙樂健康擬通過向賣方收購老股及向標的公司增資的方式,合計取得Best Formulations約71.41%股權,交易額為1.9億美元,摺合人民幣約8.71億元。此舉提升公司在全球市場的知名度和競爭力,擴大市場份額,增強長期盈利能力,強化股東回報。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.